- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Oesophageal squamous cell carcinoma (OSCC)
- Meeting Date: November 2024
- Public Summary Document (PSD) November 2024 PBAC Meeting - (PDF 895KB)
- Public Summary Document (PSD) November 2024 PBAC Meeting - (Word 594KB)
Tislelizumab – November 2024
Tislelizumab; Solution concentrate for I.V. infusion 100 mg in 10 mL; Tevimbra®
Last updated
30 May 2025